125 related articles for article (PubMed ID: 38095084)
1. Toxicological Profiling of Potential Shikimate Kinase Inhibitors Against
Jhangiani A; Panda V; Sukheja A; Thomas S; Dusseja P; Pandya S; Chintakrindi A
Altern Lab Anim; 2024 Jan; 52(1):10-27. PubMed ID: 38095084
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential inhibitors of Mycobacterium tuberculosis shikimate kinase: molecular docking, in silico toxicity and in vitro experiments.
Freitas de Freitas T; Roth CD; Abbadi BL; Hopf FSM; Perelló MA; de Matos Czeczot A; de Souza EV; Borsoi AF; Machado P; Bizarro CV; Basso LA; Timmers LFSM
J Comput Aided Mol Des; 2023 Mar; 37(3):117-128. PubMed ID: 36547753
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel antimicrobial compounds targeting Mycobacterium tuberculosis shikimate kinase using in silico hierarchical structure-based drug screening.
Kawamoto S; Hori C; Taniguchi H; Okubo S; Aoki S
Tuberculosis (Edinb); 2023 Jul; 141():102362. PubMed ID: 37311288
[TBL] [Abstract][Full Text] [Related]
4. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
Simithy J; Reeve N; Hobrath JV; Reynolds RC; Calderón AI
Tuberculosis (Edinb); 2014 Mar; 94(2):152-8. PubMed ID: 24429106
[TBL] [Abstract][Full Text] [Related]
5. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
Rajput VS; Mehra R; Kumar S; Nargotra A; Singh PP; Khan IA
Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
[TBL] [Abstract][Full Text] [Related]
6. Shikimate Kinase Inhibitors: An Update on Promising Strategy against
Rajput VS; Runthala A; Khan IA
Curr Drug Targets; 2023; 24(5):388-405. PubMed ID: 36752299
[TBL] [Abstract][Full Text] [Related]
7. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone.
Simithy J; Fuanta NR; Hobrath JV; Kochanowska-Karamyan A; Hamann MT; Goodwin DC; Calderón AI
Biochim Biophys Acta Proteins Proteom; 2018; 1866(5-6):731-739. PubMed ID: 29654976
[TBL] [Abstract][Full Text] [Related]
9. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
10. Slow-Binding Inhibition of Mycobacterium tuberculosis Shikimate Kinase by Manzamine Alkaloids.
Simithy J; Fuanta NR; Alturki M; Hobrath JV; Wahba AE; Pina I; Rath J; Hamann MT; DeRuiter J; Goodwin DC; Calderón AI
Biochemistry; 2018 Aug; 57(32):4923-4933. PubMed ID: 30063132
[TBL] [Abstract][Full Text] [Related]
11. Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials.
Gordon S; Simithy J; Goodwin DC; Calderón AI
Perspect Medicin Chem; 2015; 7():9-20. PubMed ID: 25861218
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Development of potential proteasome inhibitors against
Tyagi R; Srivastava M; Jain P; Pandey RP; Asthana S; Kumar D; Raj VS
J Biomol Struct Dyn; 2022 Mar; 40(5):2189-2203. PubMed ID: 33074049
[TBL] [Abstract][Full Text] [Related]
14.
Qureshi KA; Azam F; Fatmi MQ; Imtiaz M; Prajapati DK; Rai PK; Jaremko M; Emwas AH; Elhassan GO
PeerJ; 2023; 11():e14502. PubMed ID: 36935926
[TBL] [Abstract][Full Text] [Related]
15. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid.
Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2004 Dec; 60(Pt 12 Pt 2):2310-9. PubMed ID: 15583379
[TBL] [Abstract][Full Text] [Related]
16. The mode of action of recombinant Mycobacterium tuberculosis shikimate kinase: kinetics and thermodynamics analyses.
Rosado LA; Vasconcelos IB; Palma MS; Frappier V; Najmanovich RJ; Santos DS; Basso LA
PLoS One; 2013; 8(5):e61918. PubMed ID: 23671579
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
18. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
19.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
20. Exploring biogenic chalcones as DprE1 inhibitors for antitubercular activity via in silico approach.
Rathod S; Chavan P; Mahuli D; Rochlani S; Shinde S; Pawar S; Choudhari P; Dhavale R; Mudalkar P; Tamboli F
J Mol Model; 2023 Mar; 29(4):113. PubMed ID: 36971900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
